During the last session, Kymera Therapeutics Inc (NASDAQ:KYMR)’s traded shares were 0.64 million, with the beta value of the company hitting 2.18. At the end of the trading day, the stock’s price was $32.89, reflecting an intraday gain of 1.08% or $0.35. The 52-week high for the KYMR share is $53.27, that puts it down -61.96 from that peak though still a striking 11.61% gain since the share price plummeted to a 52-week low of $29.07. The company’s market capitalization is $2.14B, and the average trade volume was 560.21K shares over the past three months.
Kymera Therapeutics Inc (KYMR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.22. KYMR has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.88.
Kymera Therapeutics Inc (NASDAQ:KYMR) trade information
Kymera Therapeutics Inc (KYMR) registered a 1.08% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.08% in intraday trading to $32.89, hitting a weekly high. The stock’s 5-day price performance is 4.91%, and it has moved by -14.64% in 30 days. Based on these gigs, the overall price performance for the year is -21.50%.
The consensus price target of analysts on Wall Street is $56, which implies an increase of 41.27% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $55 and $57 respectively. As a result, KYMR is trading at a discount of -73.3% off the target high and -67.22% off the low.
Kymera Therapeutics Inc (KYMR) estimates and forecasts
In the rating firms’ projections, revenue will increase 34.28% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 11.38M as predicted by 18 analyst(s). Meanwhile, a consensus of 18 analyst(s) estimates revenue growth to 12.9M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 10.29M and 25.65M respectively. In this case, analysts expect current quarter sales to grow by 10.67% and then drop by -49.70% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -26.36%. While earnings are projected to return -20.69% in 2025, the next five years will return -10.79% per annum.
KYMR Dividends
Kymera Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 6.0 million shares, is of BAKER BROS. ADVISORS LP’s that is approximately 8.2069% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $178.98 million.
Also, the Mutual Funds coming in first place with the largest holdings of Kymera Therapeutics Inc (KYMR) shares are Price (T.Rowe) New Horizons Fund and Vanguard Specialized-Health Care Fund . Data provided on Dec 31, 2024 indicates that Price (T.Rowe) New Horizons Fund owns about 3.09 shares. This amounts to just over 4.76 percent of the company’s overall shares, with a $101.76 million market value. The same data shows that the other fund manager holds slightly less at 2.12, or about 3.26% of the stock, which is worth about $69.63 million.
